Cargando…
Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series
PURPOSE: Immune checkpoint blockade has led to a significant improvement of patient survival in metastatic colorectal cancer (CRC) with DNA mismatch repair-deficiency (dMMR)/microsatellite instability-high (MSI-H). However, not all these patients are sensitive to monoimmunotherapy. We firstly presen...
Autores principales: | Zhou, Chengjing, Jiang, Ting, Xiao, Yajie, Wang, Qiaoxuan, Zeng, Zhifan, Cai, Peiqiang, Zhao, Yongtian, Zhao, Zhikun, Wu, Dongfang, Lin, Hanqing, Sun, Chao, Zhang, Rong, Xiao, Weiwei, Gao, Yuanhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714781/ https://www.ncbi.nlm.nih.gov/pubmed/34975873 http://dx.doi.org/10.3389/fimmu.2021.784336 |
Ejemplares similares
-
Opportunities and challenges of immunotherapy for dMMR/MSI-H colorectal cancer
por: Zhang, Qi, et al.
Publicado: (2023) -
Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape
por: Mulet-Margalef, Núria, et al.
Publicado: (2023) -
Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer
por: Inamori, Koji, et al.
Publicado: (2021) -
Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers
por: Liu, Fangcen, et al.
Publicado: (2023) -
High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer
por: Mohamed, Amr, et al.
Publicado: (2021)